NervGen Undergoes Leadership Change to Facilitate Strategic Growth and Expansion Plans
In a significant development for those affected by spinal cord injuries, NervGen, a company specialising in neuroregenerative therapies, has announced positive results from a groundbreaking trial involving their product, NVG-291.
## NVG-291 Updates
The Phase 1b/2a clinical trial for NVG-291, which focuses on spinal cord injuries, has yielded encouraging results, particularly in the chronic cohort (1-10 years post-injury). This group demonstrated that NVG-291 met its primary endpoint and showed promising changes in a secondary endpoint assessing hand function[1][2]. Enrolment in the subacute cohort (20-90 days post-injury) continues[1].
NVG-291 works by promoting neurorepair and functional improvement through mechanisms such as neuronal sprouting, remyelination, and the promotion of a non-inflammatory phenotype in microglial cells[2][3]. The drug has received Fast Track designation from the FDA and Orphan Designation from the EMA for individuals with spinal cord injury[2][3].
## Landmark Trial Results
The results from the chronic cohort of the CONNECT SCI study represent the strongest signal of efficacy observed to date in spinal cord injury research, underscoring NVG-291's potential to redefine the standard of care[2][3]. NervGen is currently analysing data from the chronic cohort in preparation for sharing additional insights and engaging in regulatory discussions to advance NVG-291 toward late-stage development[2][3].
## Leadership Transition
In a move aimed at supporting strategic growth and expansion, NervGen has announced a leadership transition. This change comes as the company enters a critical phase in its history with positive data in hand from the CONNECT SCI study. Dr. Adam Rogers has been appointed as the interim CEO[2][3].
For more information about NervGen, their work, and the latest updates on NVG-291, visit their website at www.nervgen.com. The TSX Venture Exchange has no responsibility for the adequacy or accuracy of this release. A cautionary note regarding forward-looking statements is provided at www.sedarplus.ca and https://www.newsfilecorp.com/release/259101.
Email and print options are available for this news article. Further details about the trial, its results, and the company can also be found at www.connectscistudy.com. The study results have been shared on social media platforms such as Twitter, LinkedIn, and Facebook.
[1] NervGen Press Release, "NervGen Announces Positive Data from Chronic Cohort of CONNECT SCI Study," 28 April 2023, [www.nervgen.com/news/nervgen-announces-positive-data-from-chronic-cohort-of-connect-sci-study/](http://www.nervgen.com/news/nervgen-announces-positive-data-from-chronic-cohort-of-connect-sci-study/)
[2] NervGen Press Release, "NervGen Announces Leadership Transition," 29 April 2023, [www.nervgen.com/news/nervgen-announces-leadership-transition/](http://www.nervgen.com/news/nervgen-announces-leadership-transition/)
[3] NervGen Press Release, "NervGen Announces Positive Results from Chronic Cohort of CONNECT SCI Study," 28 April 2023, [www.nervgen.com/news/nervgen-announces-positive-results-from-chronic-cohort-of-connect-sci-study/](http://www.nervgen.com/news/nervgen-announces-positive-results-from-chronic-cohort-of-connect-sci-study/)
In the wake of promising results from the chronic cohort of the CONNECT SCI study, NervGen has shared positive updates about NVG-291, a drug designed for neuroregenerative therapies in health-and-wellness, specifically addressing medical-conditions like spinal cord injuries and neurological-disorders. The company's press releases detail the drug's potential to redefine the standard of care in science, as it promotes neurorepair and functional improvement in spinal cord injury patients.
